Partnering with Boehringer Ingelheim at BIO-Europe 2024
Learn about partnering with Boehringer Ingelheim at BIO-Europe 2024 and how together we can accelerate innovation in human health
Search
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Mental health: a $1 trillion burden demanding policy action
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Dedifferentiated liposarcoma (DDLPS)
An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Is artificial intelligence the future of farming?
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.